Amgen (NASDAQ:AMGN) said it expects full-year 2023 non-GAAP diluted earnings of $17.60 to $18.70, up from the previous guidance of $17.40 to $18.60. Analysts surveyed by Capital IQ expect $17.86. The company expects revenue for the year of $26.2 billion to $27.3 billion, up from the previous guidance of $26.0 billion to $27.2 billion. Analysts surveyed by Capital IQ expect $28.72 billion.

The biotechnology company guided for revenue between $26.2 billion and $27.3 billion, earnings per share of $15.38 to $16.59 and adjusted earnings between $17.60 and $18.70 a share. Amgen previously forecast revenue of $26 billion to $27.2 billion, earnings per share between $13.16 and $14.41, and adjusted earnings of $17.40 to $18.60 a share. The company said its outlook excludes any contribution from its acquisition of Horizon Therapeutics PLC, which is expected to close in the first half of 2023. Chief Executive Robert Bradway said demand for its products globally resulted in 14% volume growth in the first quarter.